FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($1.50) per share for the year, up from their previous forecast of ($2.25). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($3.25) EPS and FY2028 earnings at ($2.95) EPS.

A number of other brokerages have also weighed in on STOK. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.29.

Stoke Therapeutics Stock Up 4.5 %

NASDAQ:STOK opened at $11.48 on Friday. The firm has a market capitalization of $608.10 million, a PE ratio of -5.47 and a beta of 0.95. Stoke Therapeutics has a twelve month low of $4.09 and a twelve month high of $17.58. The stock’s 50-day simple moving average is $11.07 and its 200 day simple moving average is $12.71.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the sale, the general counsel now owns 35,142 shares in the company, valued at $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 2,586 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the transaction, the insider now directly owns 44,746 shares in the company, valued at $581,250.54. This trade represents a 5.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its position in shares of Stoke Therapeutics by 528.6% during the second quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock valued at $3,905,000 after acquiring an additional 243,083 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in shares of Stoke Therapeutics during the 3rd quarter valued at approximately $192,000. Finally, Los Angeles Capital Management LLC increased its stake in shares of Stoke Therapeutics by 54.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.